1. Home
  2. NECB vs DMAC Comparison

NECB vs DMAC Comparison

Compare NECB & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NorthEast Community Bancorp Inc.

NECB

NorthEast Community Bancorp Inc.

SELL

Current Price

$27.77

Market Cap

368.0M

Sector

Finance

ML Signal

SELL

Logo DiaMedica Therapeutics Inc.

DMAC

DiaMedica Therapeutics Inc.

SELL

Current Price

$8.20

Market Cap

352.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
NECB
DMAC
Founded
1934
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.0M
352.1M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
NECB
DMAC
Price
$27.77
$8.20
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
★ $30.00
$15.50
AVG Volume (30 Days)
33.1K
★ 211.7K
Earning Date
10-26-2026
11-11-2026
Dividend Yield
★ 3.70%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 1.46
N/A
Revenue
N/A
★ $500,000.00
Revenue This Year
$2.26
N/A
Revenue Next Year
$18.16
N/A
P/E Ratio
$18.55
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.27
$5.25
52 Week High
$28.94
$10.42

Technical Indicators

Market Signals
Indicator
NECB
DMAC
Relative Strength Index (RSI) 61.44 62.15
Support Level $25.83 $7.42
Resistance Level $28.94 $8.51
Average True Range (ATR) 0.63 0.48
MACD 0.10 -0.01
Stochastic Oscillator 92.36 66.28

Price Performance

Historical Comparison
NECB
DMAC

About NECB NorthEast Community Bancorp Inc.

NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States, including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: